
Kathryn Ann Rizzo DO
Cytopathology, Hematopathology, Anatomic Pathology
Physician
Join to view full profile
13103 E Mansfield AveDepartment of PathologySpokane Valley, WA 99216
Phone+1 509-892-2700
Fax+1 804-828-9749
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kathryn Rizzo, DO is a board certified pathologist in Spokane Valley, Washington. She is currently licensed to practice medicine in Washington, Florida, and Alaska.
Education & Training
National Institutes of Health Clinical CenterFellowship, Cytopathology, 2007 - 2008
National Institutes of Health Clinical CenterFellowship, Hematopathology, 2006 - 2007
Virginia Commonwealth University Health SystemResidency, Pathology-Anatomic and Clinical, 2003 - 2004
Rowan University School of Osteopathic MedicineClass of 2003
Certifications & Licensure
FL State License 2026 - 2028
SC State License 2011 - 2027
AK State License 2024 - 2026
AL State License 2017 - 2026
GA State License 2017 - 2026
ID State License 2024 - 2026
MT State License 2024 - 2026
American Board of Pathology Pathology - Anatomic
American Board of Pathology Cytopathology
American Board of Pathology Hematopathology- Join now to see all
Publications & Presentations
PubMed
- Metastatic Bronchoalveolar Carcinoma Presenting as Chronic Esophageal Stricture.Harish R Alappan, Daniel Gwan-Nulla, Kathryn Rizzo
ACG Case Reports Journal. 2022-11-01 - 15 citationsNOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.Anahita Dastur, AHyun Choi, Carlotta Costa, Xunqin Yin, August Williams
Clinical Cancer Research. 2019-01-01 - 47 citationsThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng
Blood. 2016-05-05















